Numaferm Revenue and Competitors

Düsseldorf, Germany

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Numaferm's estimated annual revenue is currently $2.4M per year.(i)
  • Numaferm's estimated revenue per employee is $130,667

Employee Data

  • Numaferm has 18 Employees.(i)
  • Numaferm grew their employee count by -18% last year.

Numaferm's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CEOReveal Email/Phone
3
Chief Operating OfficerReveal Email/Phone
4
Scientist Downstream Processing & AnalyticsReveal Email/Phone
5
Associate ScientistReveal Email/Phone
6
Senior Scientist Downstream Processing & AnalyticsReveal Email/Phone
7
Senior ScientistReveal Email/Phone
8
BTA Downstream Processing & AnalyticsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.6M13-24%N/AN/A
#2
$18.3M13118%N/AN/A
#3
$1.6M2441%N/AN/A
#4
$62.8M35911%N/AN/A
#5
$5.2M420%N/AN/A
#6
$14M988%N/AN/A
#7
$18.8M134-20%$70MN/A
#8
$2.5M254%N/AN/A
#9
$0.9M1110%N/AN/A
#10
$12.5M8946%N/AN/A
Add Company

What Is Numaferm?

We believe that in the near future peptides have found their way into new markets and are a well-known feed stock for better products in life sciences and beyond. NUMAFERM supports you in these developments – from discovery to commercial production.

keywords:N/A

N/A

Total Funding

18

Number of Employees

$2.4M

Revenue (est)

-18%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Numaferm News

2022-04-06 - The peptide therapeutics contract API manufacturing market is ...

... Philipp Burling (Chief Financial Officer, NUMAFERM). The research includes detailed profiles of key service providers (listed below)...

2022-03-22 - Peptide Therapeutics: Contract API Manufacturing Market ...

... NSJ Prayog Life Sciences; NUMAFERM; ONL Therapeutics; OPKO Health; Oramed Pharmaceuticals; ORPEGEN Peptide Chemicals; Oryn Therapeutics...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.4M18-5%N/A
#2
$2M18-5%N/A
#3
$2.1M200%N/A
#4
$2.7M2117%N/A
#5
$4.2M22-29%N/A